The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease
Long-acting muscarinic antagonists (LAMAs) play a central role in the management of chronic obstructive pulmonary disease (COPD). Previously, only one LAMA (tiotropium) was available for the treatment of COPD, necessitating the development of other therapeutic options due to the heterogeneity of COP...
Main Authors: | François Maltais, Julie Milot |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2012-12-01
|
Series: | Therapeutic Advances in Respiratory Disease |
Online Access: | https://doi.org/10.1177/1753465812463626 |
Similar Items
-
Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
by: Zhong J, et al.
Published: (2014-06-01) -
Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease
by: Sims MW, et al.
Published: (2011-09-01) -
Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease
by: Jones PW
Published: (2015-03-01) -
Clinicopharmacological profile of the fixed-dose combination of aclidinium bromide and formoterol fumarate in the management of chronic obstructive pulmonary disease
by: K. Suresh Babu, et al.
Published: (2015-04-01) -
Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
by: Bateman Eric D, et al.
Published: (2011-04-01)